NCT07898904Recruiting
Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases
Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases From Gastroenteropancreatic Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
68-Ga-DOTATATE is a radiotracer targeting somatostatin receptors (SSTR). In this study, we investigated the diagnostic efficacy of delayed \^68\^Ga-DOTATATE PET/MR in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and liver metastases, and performed a head-to-head comparison with conventional 68-Ga-DOTATATE PET/CT.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 46 (estimated)
- First submitted
- 20 Oct 2026
- Start date
- 1 Dec 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT07898904
What you commit to
- Study type: Observational
- Planned participants: 46
- From 1 Dec 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- (a) unavailability of surgical, pathological or long-term follow-up data; (b) non-compliance with age eligibility criteria or presence of comorbidities compromising protocol adherence
Who the study is looking for
- (a)Histologically confirmed well-differentiated GEP-NETs via biopsy or surgical resection in adults aged 18-80 years,(b) confirmed or suspected liver metastases, as determined by previous imaging studies or PET/CT scans,(c) availability of comprehensive surgical reports, pathological findings, comparative data, and clinical follow-up outcomes for analysis,(d) absence of PET/MR contraindications , with voluntary participation and signed informed consent forms adhering to ethical and research guidelines
Age in the registry: 30 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.